These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1549199)

  • 21. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 23. [Psychiatric complications of L-dopa: physiopathology and treatment].
    Castro-García A
    Rev Neurol; 1997 Aug; 25 Suppl 2():S157-62. PubMed ID: 9280683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newly-diagnosed Parkinson's disease: a therapeutic update.
    Pleet AB
    Geriatrics; 1992 Jan; 47(1):24-9. PubMed ID: 1729144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy.
    Simsek T; Eryilmaz T; Acaroglu G
    Int J Clin Pract; 2005 Mar; 59(3):287-90. PubMed ID: 15857324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
    Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
    Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
    Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individualization of drug therapy for the parkinsonian patient.
    JAMA; 1975 Sep; 233(11):1198-201. PubMed ID: 240043
    [No Abstract]   [Full Text] [Related]  

  • 38. [Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
    Piccirilli M; Quartesan R
    Clin Ter; 1976 Mar; 76(5):467-77. PubMed ID: 991553
    [No Abstract]   [Full Text] [Related]  

  • 39. [Side-effects of L-dopa therapy].
    Girke W; Xenakis Ch
    Dtsch Med Wochenschr; 1975 Oct; 100(42):2165-9. PubMed ID: 1100342
    [No Abstract]   [Full Text] [Related]  

  • 40. Improvement in Severe Orthostatic Hypotension Following Carbidopa Dose Reduction.
    Lau ACW; Diggle JL; Bring PP
    Can J Neurol Sci; 2018 Mar; 45(2):252-253. PubMed ID: 29262877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.